α-bisabolol Is an Effective Proapoptotic Agent against BCR-ABL+ Cells in Synergism with Imatinib and Nilotinib

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Bonifacio, Massimiliano ^a   Rigo, Antonella ^a   Guardalben, Emanuele ^a   Bergamini, Christian ^b   Cavalieri, Elisabetta ^c   Fato, Romana ^b   Pizzolo, Giovanni ^a   Suzuki, Hisanori ^c   Vinante, Fabrizio ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BISABOLOL; IMATINIB; NILOTINIB; REACTIVE OXYGEN METABOLITE;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL LEVEL; CELL MEMBRANE; CELL STRAIN CML T1; CELL STRAIN K 562; CELL STRAIN LAMA 84; CELL VIABILITY; CELLULAR PARAMETERS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG UPTAKE; HUMAN; HUMAN CELL; INTRACELLULAR SPACE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL TRANSITION PORE OPENING; OXYGEN CONSUMPTION; PLASMA MEMBRANE INTEGRITY;

APOPTOSIS; CELL LINE, TUMOR; CELL MEMBRANE; CELL SURVIVAL; DRUG SYNERGISM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKOCYTES, MONONUCLEAR; PIPERAZINES; PYRIMIDINES; REACTIVE OXYGEN SPECIES; SESQUITERPENES;

EID: 84867063824     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046674     Document Type: Article

References (31)

1. Cowan-Jacob SW, Guez V, Fendrich G, Griffin JD, Fabbro D, et al. (2004) Bcr-Abl kinase mutations and drug resistance to imatinib (STI571) in chronic myelogenous leukemia. Mini Rev Med Chem 4: 285-299.
2. Jorgensen HG, Allen EK, Jordanides NE, Mountford JC, Holyoake TL, (2007) Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 109: 4016-4019.
3. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, et al. (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 year: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11: 1029-1035.
4. Cortes J, Hochhaus A, Hughes T, Kantarjian H, (2011) Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J Clin Oncol 29: 524-531.
5. Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, et al. (2001) In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97: 1999-2007.
6. Yu C, Krystal G, Dent P, Grant S, (2002) Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. Clin Cancer Res 8: 2976-2984.
7. Borthakur G, Kantarjian H, Daley G, Talpaz M, O'Brien S, et al. (2006) Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer 106: 346-352.
8. Hu Z, Pan XF, Wu FQ, Ma LY, Liu DP, et al. (2009) Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia. PLoS One 4: e6257.
9. Irvine DA, Zhang B, Allan EK, Holyoake TL, Dorsch M, et al. (2009) Combination of the Hedgehog Pathway Inhibitor LDE225 and Nilotinib eliminates Chronic Myeloid Leukemia Stem and Progenitor Cells. Blood (ASH Annual Meeting abstracts) 114: 1428.
10. Zhang B, Strauss AC, Chu S, Li M, Ho Y, et al. (2010) Targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 17: 427-442.
11. Jakovlev V, Isaac O, Thiemer K, Kunde R, (1979) Pharmacological investigations with compounds of chamomile II. New investigations on the antiphlogistic effects of (-)-alpha bisabolol and bisabolol oxides. Planta Med 35: 125-140.
12. Cavalieri E, Mariotto S, Fabrizi C, de Prati AC, Gottardo R, et al. (2004) Alpha-Bisabolol, a nontoxic natural compound, strongly induces apoptosis in glioma cells. Biochem Biophys Res Commun 315: 589-594.
13. Cavalieri E, Rigo A, Bonifacio M, de Prati AC, Guardalben E, et al. (2011) Pro-apoptotic activity of α-bisabolol in preclinical models of primary human acute leukemia cells. J Transl Med 9: 45.
14. Darra E, Abdel-Azeim S, Manara A, Shoji K, Marechal JD, et al. (2008) Insight into the apoptosis-inducing action of alpha-bisabolol towards malignant tumor cells: involvement of lipid rafts and Bid. Arch Biochem Biophys 476: 113-123.
15. Patra SK, Bettuzzi S, (2007) Epigenetic DNA-methylation regulation of genes coding for lipid raft-associated components: a role for raft proteins in cell transformation and cancer progression. Oncol Rep 17: 1279-1290.
16. Cavalieri E, Bergamini C, Mariotto S, Leoni S, Perbellini L, et al. (2009) Involvement of the mitochondrial permeability transition pore opening in α-bisabolol induced apoptosis. FEBS Journal 276: 3990-4000.
17. Eskes R, Desagher S, Antonsson B, Martinou JC, (2000) Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol Cell Biol 20: 929-935.
18. Morselli E, Galluzzi L, Kepp O, Vicencio JM, Criollo A, et al. (2009) Anti- and pro-tumor functions of autophagy. Biochim Biophys Acta 1793: 1524-1532.
19. Vinante F, Rigo A, Papini E, Cassatella MA, Pizzolo G, (1999) Heparin-binding epidermal growth factor-like growth factor/diphtheria toxin receptor expression by acute myeloid leukemia cells. Blood 93: 1715-1723.
20. Vinante F, Marchi M, Rigo A, Scapini P, Pizzolo G, et al. (1999) Granulocyte-macrophage colony-stimulating factor induces expression of heparin-binding epidermal growth factor-like growth factor/diphtheria toxin receptor and sensitivity to diphtheria toxin in human neutrophils. Blood 94: 3169-3177.
21. Rigo A, Gottardi M, Damiani E, Bonifacio M, Ferrarini I, et al. (2012) CXCL12 and [N33A]CXCL12 in 5637 and HeLa cells: regulating HER1 phosphorylation via calmodulin/calcineurin. PLoS One 7: e34432.
22. Chou TC, Talalay P, (1984) Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 4: 450-454.
23. Imai H, Narashima K, Arai M, Sakamoto H, Chiba N, et al. (1998) Suppression of leukotriene formation in RBL-2H3 cells that overexpressed phospholipid hydroperoxide glutathione peroxidase. J Biol Chem 273: 1990-1997.
24. Sao Pedro A, Detoni C, Ferreira D, Cabral-Albuquerque E, Sarmento B, (2009) Validation of a high-performance liquid chromatography method for the determination of (-)-α-bisabolol from particulate systems. Biomed Chromatogr 23: 966-972.
25. Chretien D, Bénit P, Chol M, Lebon S, Rötig A, et al. (2003) Assay of mitochondrial respiratory chain complex I in human lymphocytes and cultured skin fibroblasts. Biochem Biophys Res Commun 301: 222-224.
26. Butturini E, Cavalieri E, Carcereri de Prati A, Darra E, Rigo A, et al. (2011) Two naturally occurring terpenes, dehydrocostuslactone and costunolide, decrease intracellular GSH content and inhibit STAT3 activation. PLoS One 6: e20174.
27. Costarelli L, Malavolta M, Giacconi R, Cipriano C, Gasparini N, et al. (2010) In vivo effect of alpha-bisabolol, a non toxic sesquiterpene alcohol, on the induction of spontaneous mammary tumors in HER-2/neu transgenic mice. Oncol Res 18: 409-418.
28. Seki T, Kokuryo T, Yokoyama Y, Suzuki H, Itatsu K, et al. (2011) Antitumor effect of α-bisabolol against pancreatic cancer. Cancer Sci 102: 2199-2205.
29. Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, et al. (2009) Targeting autophagy potentiates tyrosine kinase inhibito-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 119: 1109-1123.
30. Ghobrial IM, Witzig TE, Adjei AA, (2005) Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 55: 178-194.
31. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G, (2007) Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 8: 741-752.